Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia
Restricted accessEditorialFirst published online September, 2020
Cost-effectiveness of rivaroxaban plus aspirin (dual pathway inhibition) for prevention of ischaemic events in patients with cardiovascular disease: on top optimisation of secondary prevention medication in the context of COVID-19 pandemia
AnandSSYusufS.; for the Warfarin Antiplatelet Vascular Evaluation Trial Investigators, WAVE.Oral anticoagulants and antiplatelet therapy and peripheral arterial disease. N Engl J Med2007;
357: 217–227.
2.
BhattDLFoxKAAHackeW, et al.
Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med2006;
354: 1706–1717.
3.
BonocaMPBhattDLCohenM, et al.; PEGASUS-TIMI 54 Steering Committee and Investigators.
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med2015;
372: 1791–1800.
4.
HiattWRFowkesFGRHeizerG, et al.; for the EUCLID Trial Steering Committee and Investigators.
Ticagrelor versus clopidogrel in symptomatic peripheral artery disease. N Engl J Med2017;
376: 32–40.
5.
MorrowDABraunwaldEBonocaMP, et al.; TRA 2P–TIMI 50 Steering Committee and Investigators.
Vorapaxar in the secondary prevention of atherothrombotic events. N Engl J Med2012;
366: 1404–1413.
6.
MegaJLBraunwaldEWiviottSD, et al.; for the ATLAS ACS 2–TIMI 51 Investigators.
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med2012;
366: 9–19.
7.
EikelboomJWConnollySJBoschJ, et al.; for the COMPASS Investigators.
Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med2017;
377: 1319–1330.
8.
AnandSSBoschJEikelboomJW, et al.; on behalf of the COMPASS Investigators.
Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet2018;
391: 219–229.
9.
PetersohnSPouwelsXRamaekersB, et al.
Rivaroxaban plus aspirin for the prevention of ischemic events in patients with cardiovascular disease: a cost-effectiveness study. Eur J Prev Cardiol, 2020; 27: 1354–1365.
NocellaCBiondi-ZoccaiGSciarrettaS, et al.
Impact of tobacco versus electronic cigarette smoking on platelet function. Am J Cardiol2018;
122: 1477–1481.
12.
SwaminathanAAmitkumarKGanapathyS, et al.
Evaluation of the impact of cigarette smoking on platelet parameters. Natl J Physiol Pharm Pharmacol2015;
5: 426–430.
13.
TakajoYIkedaHHaramakiN, et al.
Augmented oxidative stress of platelets in chronic smokers. Mechanisms of impaired platelet-derived nitric oxide bioactivity and augmented platelet aggregability. J Am Coll Cardiol2001;
38: 1320–1327.
14.
KotsevaKDe BackerGDe BacquerD, et al.
Primary prevention efforts are poorly developed in people at high cardiovascular risk: a report from the European Society of Cardiology EURObservational research Programme EUROASPIRE V survey in 16 European countries. Eur J Prev Cardiol, Epub ahead of print 20 March 2020. DOI: 10.1177/2047487320908698.
15.
KotsevaKDe BackerGDe BacquerD, et al.
Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry. Eur J Prev Cardiol2019;
26: 824–835.
16.
De SmedtDDe BackerTPetrivicM, et al.
Chronic medication intake in patients with stable coronary heart disease across Europe: Evidence from the daily clinical practice. Results from the ESC EORP European Survey of Cardiovascular Disease Prevention and Diabetes (EUROASPIRE IV) Registry. Int J Cardiol2020;
300: 7–13.
17.
RauchBDavosCHDohertyP, et al.; on behalf of the “Cardiac Rehabilitation Section”, European Association of Preventive Cardiology (EAPC).
The prognostic effect of cardiac rehabilitation in the era of acute revascularization and statin therapy: a systematic review and meta-analysis of randomized and non-randomized studies – The Cardiac Rehabilitation Outcome Study (CROS).Eur J Prev Cardiol2016;
23: 1914–1939.
18.
SalzwedelAJensenKRauchB, et al.
Effectiveness of comprehensive cardiac rehabilitation in coronary artery disease patients treated according to contemporary evidence based medicine: update of the Cardiac Rehabilitation Outcome Study (CROS-II). Eur J Prev Cardiol. Epub ahead of print 23 February 2020. DOI: 10.1177/2047487320905719
19.
GysanDMillentrupSAlbusC, et al.
Substantial improvement of primary cardiovascular prevention by a systematic score-based multimodal approach: a randomized trial: the PreFord-Study. Eur J Prev Cardiol2017;
24: 1544–1554.
20.
YangJZhengYGouX, et al.
Prevalence of comorbidities in the Novel Wuhan Coronavirus (COVID-19) infection: a systematic review and meta-analysis. Int J Infect Dis, Epub ahead of print 12 March 2020. DOI: 10.1016/j.ijid.2020.03.017.
21.
GuoTFanYChenM, et al.
Cardiovascular implications of fatal outcomes of patients with Coronarvirus Disease 2019 (COVID-19). JAMA Cardiol, Epub ahead of print 27 March 2020. DOI: 10.1001/jamacardio.2020.1017.
22.
EganGHughesCAAckmanML.Drug interactions between antiplatelet or novel oral anticoagulant medications and antiretroviral medications. Ann Pharmacother2014;
48: 734–740.
